bexarotene

(redirected from LGD1069)

bexarotene

 [bek-sar´ah-tēn]
a retinoid that modulates transcription and expression of genes involved in cellular differentiation and proliferation; used as an antineoplastic in the treatment of cutaneous T-cell lymphoma, administered orally. It is also used topically in the treatment of cutaneous lesions of T-cell lymphomas and Kaposi's sarcoma.

bexarotene

A retinoid that binds to retinoid X receptors, upregulating their activity by either removing negative transcription control or by facilitating transcription. It is FDA-approved for treating cutaneous T cell lymphoma, and has been used off label for lung and breast cancer, and Kaposi sarcoma.
Adverse effects Similar to hypervitaminosis A—headache, nausea, vomiting, lip inflammation, mucous-membrane dryness, joint pain, scaly skin, hyperlipidaemia
References in periodicals archive ?
LGD1069. inhibits tumor-induced angiogenesis via suppression of VEGF in human non-small cell lung cancer.
Peroxisome proliferator-activated receptor-[alpha] (PPAR[alpha]) and retinoid X receptor (RXR) agonists (613333 and LGD1069, respectively) were kindly provided by P.
Moreover, the PPAR[gamma] and RXR agonists rosiglitazone and LGD1069 (see Supplemental Material, Figure 1f and Figure 1i, respectively) had similar but weaker effects, whereas two different PPAR[alpha] agonists (613333 and GW590735) had no effect (see Supplemental Material, Figure 1g,h).